Effect of IDX on COVID-19 infection

Project Member(s): Hansbro, P., Johansen, M.

Funding or Partner Organisation: Noxopharm Limited
Noxopharm Limited

Start year: 2021

Summary: This project is to investigate the anti-inflammatory potential of IDX in Prof. Hansbro’s mouse model of SARS-CoV-2 induced hyperinflammation, and confirm the protective activity of IDX against COVID-19. The aim is to provide direct evidence with appropriate control cohorts of the anti-inflammatory effect of IDX in the context of SARS-CoV-2 infection, to support further clinical trials in the USA and Europe.

FOR Codes: Respiratory diseases , Respiratory System and Diseases (incl. Asthma), Infectious Diseases, Clinical health

Acknowledgement of Country

UTS acknowledges the Gadigal people of the Eora Nation, the Boorooberongal people of the Dharug Nation, the Bidiagal people and the Gamaygal people, upon whose ancestral lands our university stands. We would also like to pay respect to the Elders both past and present, acknowledging them as the traditional custodians of knowledge for these lands.